2742 ST. Joseph Boulevard
About Tetra Bio-PharmaTetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Founder: Ryan Brown and Andre Audet
CEO: Andre Rancourt
CSO: Guy Chamberland
CFO: Sabino Di Paola
FOLLOW TETRA BIO-PHARMA:
Tweets by Tetra Bio-Pharma
26 articles with Tetra Bio-Pharma
8/22/2019Companies from across the globe provide updates on their business and pipelines.
Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance
When It Comes to Cannabis, Trust in Doctors' Judgement Runs High
Media Advisory - Dr. Chamberland, Expert Spokesperson available to discuss legalization of recreational cannabis
Dr. Chamberland available to discuss legalization of recreational cannabis
Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy
Tetra Bio-Pharma Inc. have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001.
Tetra Bio-Pharma Names Guy Chamberland as Interim CEO
Tetra Bio-Pharma Inc. is pleased to announce it has closed its non-brokered private placement of 4,292,000 units at a price of $1.00 per unit for aggregate gross proceeds of $4,292,000.
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement
Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation
Neptune and Tetra Bio-Pharma announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.
Tetra Bio-Pharma Receives Health Canada Phase III Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Tetra Bio-Pharma announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company's PPP001 prescription smokable dried cannabis product.
Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis
Tetra Bio-Pharma announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.
Tetra Bio-Pharma Receives Approval from Health Canada of its Phase I Clinical Trial with PPP005 (Cannabis Oil)
Tetra Bio-Pharma announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.
Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and Its Late Stage ACMPR Application
Tetra Bio-Pharma announce that it has entered into a non-binding letter of intent (the "LOI") with a private Canadian corporation.
Tetra Bio-Pharma Reinforces Its Development Program by Signing Research & Development Agreement With Constance Therapeutics and Receiving Financial Support From NSERC
In collaboration, Tetra and Constance Therapeutics now aim to define the therapeutic mechanism and demonstrate efficacy of these cannabis extracts in the treatment of human cancers.
Tetra Bio-Pharma Provides Update on Status of Its Phase III Clinical Trial Application of Lead Drug Candidate PPP001
Tetra Bio-Pharma announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process.
The listing ceremony took place at the TMX Broadcast Centre in Toronto, Ontario. Bernard Fortier, Chief Executive Officer (CEO), and Bernard Lessard, Chief Financial Officer, represented Tetra at the listing ceremony.
Tetra Bio-Pharma Accelerates Submission of NDA to FDA & Expects To Commercialize Dronabinol XL Tablet Ahead of Schedule(1) in the U.S.
According to market research by the International Agency for Research on Cancer (2), the global CINV market will reach a valuation of US$1.88 bn by 2020, rising from its 2013 valuation of US$1.28 bn.
Tetra Bio-Pharma's Business Model and Commercialization Strategy in Line With the Canadian Government's Proposed Approach to the Regulation of Cannabis
The proposed approach to regulation recommends that cannabis-based health products are still subject to scientific review and must show significant efficacy, meet strict safety requirements and be of sufficient quality in order to gain market approval as a drug or as a natural health product.
Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M.
Tetra has received its first sales order from Sante Cannabis.
Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps and Presents its New Corporate Image
Tetra Bio-Pharma Inc., a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).